Print
Email
The United States diabetes devices and therapeutics market size is expected to record a CAGR of 13.3% during 2023-2027 to reach US$51,281.2 million by 2027, increasing from US$31,170.1 million in 2023. Over the last five years, the sector has recorded a CAGR of 12.9% to reach US$27,601.8 million in 2022 and Dexcom's strategic move marks a significant step toward advancing precision care in diabetes management. By introducing a CGM specifically designed for this population, the company aims to empower individuals to make informed decisions about their health, optimize their daily routines, and potentially delay the need for injectable therapies and insulin. While specific details about the device's features and pricing remain confidential, Dexcom's commitment to addressing the unmet needs of this broader market signals a promising future for the integration of innovative technologies in Type 2 diabetes management.
With an estimated target market of many million individuals in the United States, Dexcom recognizes the significant unmet need for continuous glucose sensing in this broader population. The new CGM is designed to address the specific requirements of Type 2 diabetes patients who have yet to require insulin, offering personalized insights without the burden of unnecessary alarms and alerts. It's innovative approach and commitment to meeting the unique demands of this patient group have the potential to revolutionize Type 2 diabetes care.
Dexcom's analysis reveals that non-insulin-using Type 2 diabetes patients seek assistance in comprehending the impact of lifestyle choices on their blood glucose levels. This demographic wants tools to improve their diet and exercise regimens because they are afraid of moving on to injectable medications like insulin.
Despite their motivation, the adoption rate of CGMs among these individuals remains extremely low, with fewer than 5% currently using such devices. Recognizing this glaring gap, Dexcom aims to bridge it by tailoring its G7 CGM to meet the specific needs and preferences of this patient demographic.
Unlike their previous target population, Dexcom's non-insulin patients require a different set of priorities. Consequently, the company is developing a multifaceted approach to address their unique needs. This includes forming digital health partnerships, pursuing reimbursement options, and building a customized software package tailored to this population. By connecting the dots between diet, physical activity, and medication, the new CGM aims to provide a comprehensive understanding of glucose dynamics. Dexcom's customer insights highlight the inadequacy of current products on the market, further reinforcing the necessity for a CGM that fully caters to the needs of this underrepresented patient group.
Dexcom's upcoming introduction of a CGM aimed at non-insulin-using Americans with Type 2 diabetes is set to revolutionize the way glucose levels are monitored and managed in this patient population. With a focus on personalized insights, optimized nutrition and exercise routines, and a user-friendly experience, Dexcom is poised to meet the unique needs of this underrepresented group.
BioIntel360 suggests that by closing the gap in continuous glucose sensing, Dexcom's innovation has the potential to empower millions of individuals with Type 2 diabetes to take control of their health, leading to improved outcomes and enhanced quality of life. In a bold move to cater to the needs of non-insulin-using Americans with Type 2 diabetes, Dexcom, a leading continuous glucose monitoring (CGM) company, is set to introduce a groundbreaking device based on their G7 technology.
